16
The Novel Tablet
The Novel Tablet
The ContributorsThe Contributors Commercialization Commercialization
Plan by:Plan by: Sarah FisterSarah Fister
Merchandising Merchandising ManagementManagement
Jimmy NeyhartJimmy Neyhart Business Business
AdministrationAdministration Carly StoughtonCarly Stoughton
Computer ScienceComputer Science
Research contributors: Dr. Jim Ayres
Inventor, OSU College of Pharmacy
Dr. Mark Christensen Inventor, OSU College
of Pharmacy Bill Newman
Mentor, Hewlett-Packard
Novel
Tablet
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
• An effective, long-lasting drug delivery system does not exist
• Customers are inconvenienced by taking multiple doses throughout the day
• Current drug delivery systems are inconsistent in their dosage administration
The ProblemThe Problem
Novel
Tablet
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
The SolutionThe Solution
““Mean fever reductions and mean acetaminophen concentration in saliva. Observed temperature Mean fever reductions and mean acetaminophen concentration in saliva. Observed temperature and mean acetaminophen concentration over time were observed in different groups of children. and mean acetaminophen concentration over time were observed in different groups of children.
Open circles, mean acetaminophen concentration in saliva of children who absorb acetaminophen Open circles, mean acetaminophen concentration in saliva of children who absorb acetaminophen slowly…closed squares mean fever reduction” – U.S. Patent #5,766,623slowly…closed squares mean fever reduction” – U.S. Patent #5,766,623
Novel
Tablet
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
Novel Tablets provide 12-16 hours of steady Novel Tablets provide 12-16 hours of steady dosage of active compounddosage of active compound
The DescriptionThe Description
Novel
Tablet
The tablets consist of: The tablets consist of: “A chewable tablet made “A chewable tablet made from drug delivery pellets, each drug delivery from drug delivery pellets, each drug delivery
pellet comprising: a pellet comprising: a core portion comprising an core portion comprising an active agentactive agent; and a coating for the core portion, ; and a coating for the core portion, the coating and core portion forming a discrete the coating and core portion forming a discrete body, the coating comprising a body, the coating comprising a hydrophilic gel-hydrophilic gel-
forming agent undercoatingforming agent undercoating or mixed with or mixed with a a polymeric rate-controlling materialpolymeric rate-controlling material”.”. (U.S. (U.S.
Patent #5,766,623)Patent #5,766,623)
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
12 = active agent
20 = hydrophilic gel-forming agent layer
22 = polymeric rate-controlling material layer
*** An additional layer (not shown) of binder, disintegrant, and flavor is added over layer 22
The DescriptionThe Description
Novel
Tablet
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
12-16 hour relief12-16 hour relief Chewable, good-tasting tabletChewable, good-tasting tablet InexpensiveInexpensive Manufactured with existing equipmentManufactured with existing equipment Patent secured – ready to goPatent secured – ready to go FDA-approved ingredientsFDA-approved ingredients Most drug molecules compatibleMost drug molecules compatible Few direct competitorsFew direct competitors
The BenefitsThe Benefits
Novel
Tablet
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
Given current industry developments, we Given current industry developments, we must commercialize soon. Licensing is the must commercialize soon. Licensing is the most time effective, cost effective solutionmost time effective, cost effective solution
First-mover advantageFirst-mover advantage IP protected via patentIP protected via patent Pharmaceutical drug patent extensionsPharmaceutical drug patent extensions
Why License?Why License?
Novel
Tablet
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
Company interested in R&D Company interested in R&D investmentinvestment
Licensee open to innovative ideasLicensee open to innovative ideas Has an entrepreneurial spiritHas an entrepreneurial spirit US roots with worldwide expansionUS roots with worldwide expansion Segments in OTC and Segments in OTC and
pharmaceutical marketspharmaceutical markets
Licensee CriteriaLicensee Criteria
Novel
Tablet
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
Exclusive five year licenseExclusive five year license Cost of license = $1.5 billionCost of license = $1.5 billion Royalty fees based on net salesRoyalty fees based on net sales Licensee responsible for patent maintenance feesLicensee responsible for patent maintenance feesNet Sales ($US)Net Sales ($US) Net Sales ($US)Net Sales ($US)
<$1M<$1M 9%9% $4-8M$4-8M 5%5%
$1-2M$1-2M 8%8% $8-12M$8-12M 4%4%
$2-4M$2-4M 6%6% >$12M>$12M 2%2%
The LicenseThe License
Novel
Tablet
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
Works with virtually any prescriptive molecule:Works with virtually any prescriptive molecule:
Cardiovascular:Cardiovascular: Hypertensives: CoregHypertensives: Coreg
RespiratoryRespiratory Histamines: Advair Histamines: Advair
The OpportunityThe Opportunity
Novel
Tablet
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
20042004RevenueRevenue
20052005RevenueRevenue
20062006RevenueRevenue
Ave. Ave. GrowthGrowth
Projected NT Projected NT RevenueRevenue
CoregCoreg $432M$432M $573M$573M $779M$779M +24%+24% +$211M+$211M
AdvairAdvair $2,441M$2,441M $3,003M$3,003M $3,313M$3,313M +35%+35% +$1,259M+$1,259M
Projections based on:
• 10% additional premium per tablet
• 3% additional growth for the following year
• Implementation of the Novel Tablet delivery system
GlaxoSmithKline FinancialsGlaxoSmithKline Financials
Novel
Tablet
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
Large over-the-counter marketLarge over-the-counter market The longest lasting drug on the market is Tylenol-8; The longest lasting drug on the market is Tylenol-8;
not a constant dosagenot a constant dosage Novel Tablets can be combined with a variety of Novel Tablets can be combined with a variety of
medicationsmedications Useful for chronic pain (i.e. back pain, headaches)Useful for chronic pain (i.e. back pain, headaches) Reduces amount people have to Reduces amount people have to
take in a daytake in a day No other drug on the market No other drug on the market
provides relief this longprovides relief this long
The Future: NearThe Future: Near
Novel
Tablet
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
The Future: Near: The Future: Near: IssuesIssues
Novel
Tablet
CompetitorsCompetitors Consumer adaptabilityConsumer adaptability
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
Drug cocktailsDrug cocktailsCustom drug combinationsCustom drug combinationsInfinite possibilitiesInfinite possibilities
The Future: FurtherThe Future: Further
Novel
Tablet
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
AcknowledgementsAcknowledgements
Dr. Jim AyersDr. Jim Ayers InventorInventorDr. Mark ChristensonDr. Mark Christenson Mentor; College of PharmacyMentor; College of PharmacyRay DandeneauRay Dandeneau MentorMentorBill NewmanBill Newman Mentor; Hewlett PackardMentor; Hewlett PackardJohn TurnerJohn Turner ProfessorProfessor
Oregon State UniversityOregon State University
Novel
Tablet
Contributors Problem Solution Description Benefits
Why License License Details Opportunity Financials Future
